Filtrer vos résultats
- 4
- 3
- 1
- 4
- 3
- 1
- 4
- 4
- 4
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 4
- 4
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
triés par
|
Validation of IBD-disk for the assessment of daily-life burden of patients with inflammatory bowel diseaseJournal of Crohn's and Colitis, 2020, 14 (1), pp.S272
Article dans une revue
hal-03551538v1
|
|||
Acceptability of treatment regimen in inflammatory bowel disease: Results from a prospective nationwide study (ACCEPT2)2020, pp.S337-S338
Autre publication scientifique
hal-03551532v1
|
|||
|
Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective studyJournal of Crohn's and Colitis, 2020, 14 (1), pp.S547. ⟨10.1093/ecco-jcc/jjz203.793⟩
Article dans une revue
hal-03551537v1
|
||
Development of a small bowel capsule endoscopic index of severity in patients with Crohn's diseaseJournal of Crohn's and Colitis, 2016, 10 (1), pp.S210
Article dans une revue
hal-03553397v1
|